Join us as we speak to Dr. Lori Muffly and Dr. Matthew Frank from Stanford Medicine in Stanford, CA, about the recent advancements in testing for Minimal/Measurable Residual Disease (MRD). In this episode, we delve into what MRD is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future.

Mentioned

• Minimal/Measurable Residual Disease
• A Medication Resource for Blood Cancer Patients
• Minimal/Measurable Residual Disease Chart 
• Stanford Medicine Research
• CAPP-Seq test – Ash Alizadeh
• Acute Lymphoblastic Leukemia (ALL)  

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program Free Nutrition Consultations

Support for this episode provided by Genentech, Inc. and Biogen.

The post Exploring Minimal/Measurable Residual Disease (MRD) first appeared on The Bloodline with Blood Cancer United Podcast.